Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June29

POSTE S S Trak 132-134

12323 Increases in the levels of peripheral blood CD34+ CFU-Cs in HIV-infected
individuals upon commencement of combination antiretroviral drug
therapy
GregorB. Adams*;M.C. Poznansky;M.O. McClure;J.N. Weber;
A.S. Pym, UK
12324 Ritonavir + saquinavir as a rescue therapy after indinavirfailure
Antonio Antela*; M.J. Perez-Elias;.L. Casado; F. Dronda; R. Sabido;
L. Moreno; C. Quereda, Spain
12325 Frequency and causes of discontinuation of protease inhibitor (PI)
therapy in routine clinical practice
Elena Ferrer*; E. Consiglio; D. Podzamczer; I. Grau; J.M. Rambn;
M. Santin; F. Gudiol, Barcelona, Spain
12326 Efficacy and hepatic tolerance of treatment with protease inhibitors
in HIV and hepatitis C virus (HCV) co-infected patients
Bernard Jarrousse*; P. Cohen; P. Soussan; P. Berlurean; F. Legal;
L. Guillevin; P. Deny, France
12327 Diabetes and use of protease inhibitors
BettyJ. Dong*; C.I. Gruta; J.. Legg, USA
12328 Urine acidification and the risk of nephrolithiasis due to indinavir
David Zucman*; A.D. Dayras; A.T. Teixeita; S.B. Burnel; O.B. Bletry,
France
12329 Effect of nelfinavir/indinavir/delavirdine in HIV+ patients with extensive
antiviral experience
Larry Lyle*; G. Strebel, USA
12330 Efficacy and durability of ritonavir/saquinavir (RTV/SQV) as salvage
therapy after failure of initial protease inhibitor (PI) regimen
Joel E. Gallant*; Joel E. Gallant; S. Barnett; C. Raines; C. Hall, USA
12331 Changes in CD4+ cell count and the risk of opportunistic infections or
death after highly active antiretroviral treatment
Geneviene Chene*; Christine Binquet; J.F. Moreau; D. Neau; J. Ceccaldi;
F. Dabis, France
12332 Ongoing experience with nelfinavir substitution for indinavir or
ritonavir/saquinavir in HIV+ suppressed below 400 copies/ml
Calvin J. Cohen*; J.A. Hellinger; A.J. Stein; J. Gallant; J. Gathe;
P. Keiser, USA
12333 Tolerance,adverse reactions and compliance of children treated
with ritonavir in combination therapy for HIV-infection at IMIP's
Hospital-Recife, Brazil
Edvaldo Souza*; G.A. Silva; W. Araujo; A.C. Montarroyos; M. Veras;
N. Correia, Brazil
12334 Protease inhibitors containing regimens:The reasons of absence
of initial virological response
Lise Cuzin*; P. Duchesne; Z. Elias; E. Bonnet; P. Massip, France
12335 indinavirwith stavudine vs. IDV alone vs. stavudine alone in zidovudine
experienced, HIV-infected patients
Roy T. Steigbigel*; D. Cooper; N. Clumeck; K. Ghosh; B.-K Nguyen,
USA
12336 Efficacy and safety of the combination of ritonavir plus saquinavir,
with two nucleoside analogues
Rafael Rodriguez-Rosado*; V. Soriano; I. Jimenez; P. Anton;
J. Gonzalea-Lahoz, Spain

12337 Saquinavir vs indinavir in triple drug theraphy
Fredy Suter*; F. Maggiolo; P. Bottura; A. Pirali; G. Marchetti;
G. Pravettoni, Italy
12338 Virological and immunological effectiveness of protease inhibitor
therapy in protease inhibitor-experienced patients
Ma Jesus Perez-Elias*; J.L. Casado; A. Antella; F. Dronda; J. Blazquez;
V. Muhoz; P. Marti-Belda, Spain
12339 In vitro antiviral activity and pharmacokinetic (PK) profiles of KNI 272
when combined with other protease inhibitors (PIs)
Hideharu Sato* M.S. Shintani; T.M. Mimoto; K.T. Terashima;
H.H. Hayashi; H.M. Mitsuya, Japan
12340 Experiences in protease inhibitor use in patients heavily pretreated
with reverse transcriptase inhibitors
Heinz-August Horst*; C.H. Hoffman, Germany
12341 Follow-up of antigen-specific CD4 cell function in HAART patients
Valerio Del Bono*; D. Fenoglio; E. Pontali; M.P. Terranova; E. Donelli;
F. Manca; D. Bassetti, Italy
12342 Viral load reduction after changing from nelfinavir- to indinavircontaining regimens and associated resistance mutations
John T. Brooks*; Martha Vander Vliet; Paul E. Sax, USA
12343 Dramatically declining morbidity and mortality in an ambulatory
HIV-infected population
Frank Palella*; A. Moorman; R. Delaney; M. Loveless; J. Fuhrer;
D. Aschman; S. Holmberg, USA
12344 Use of protease inhibitors in HIV-infected children
Robert C. Stevens*;J. McCauley; P. Flynn;J. Rodman, USA
12345 Clinical manifestations of HIV-infections in the era of highly active
antiretroviral treatment (HAART) in France
Dominique Costagliola, France
12346 Experience with protease inhibitors in HIV/AIDS patients
Sergio Lupo*;J. Benetucci;A. Casiro; H. Roland; R. Bortolozzi;
0. Garcia Messina; M. Pedrola, Argentina
12347 The impact of baseline antiretroviral therapy in the outcome of CMV
retinitis treated with oral ganciclovir (OGCV)
Marcelo H. Losso*; A.-D. Duran; N.-F. Flaster; J.-T. Tessler, Argentina
NOTES

IUE)

ONFERENCE WORKBOOK

35